The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Exportin 1 as a therapeutic target against chemoresistance in small cell lung cancer.
 
Alvaro Quintanal-Villalonga
Honoraria - AstraZeneca Canada
Patents, Royalties, Other Intellectual Property - Patent application related to abstract, entitled: “Methods for predicting and treating chemoresistance in small cell lung cancer patients.”
 
Hirokazu Taniguchi
No Relationships to Disclose
 
Yuan Hao
No Relationships to Disclose
 
Andrew Chow
Stock and Other Ownership Interests - 10X Genomics; Illumina; Moderna Therapeutics; Pacific Biosciences; PDS Biotechnology
 
Yingqian A. Zhan
No Relationships to Disclose
 
Umesh Bhanot
No Relationships to Disclose
 
Juan Qiu
No Relationships to Disclose
 
Elisa de Stanchina
No Relationships to Disclose
 
Richard P. Koche
No Relationships to Disclose
 
John T. Poirier
Patents, Royalties, Other Intellectual Property - Patent entitled: “Methods for predicting and treating chemoresistance in small cell lung cancer patients.”
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bridge Medicines; Daiichi Sankyo/UCB Japan; Earli; Epizyme; Genentech/Roche; Harpoon Therapeutics; Ipsen; Jazz Pharmaceuticals; Kowa; Merck; Syros Pharmaceuticals; Syros Pharmaceuticals
Research Funding - Merck (Inst); Roche/Genentech (Inst)